Who are Adjuvant tislelizumab plus lenvatinib's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/adjuvant-tislelizumab-plus-lenvatinib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Adjuvant tislelizumab plus lenvatinib — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adjuvant tislelizumab plus lenvatinib (Adjuvant tislelizumab plus lenvatinib) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1 inhibitor + multi-targeted tyrosine kinase inhibitor combination. Area: Oncology.

phase 3 PD-1 inhibitor + multi-targeted tyrosine kinase inhibitor combination PD-1 (tislelizumab); FGFR, VEGFR, RET, KIT (lenvatinib) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Adjuvant tislelizumab plus lenvatinib (Adjuvant tislelizumab plus lenvatinib) — Guangxi Medical University. Tislelizumab blocks PD-1 on immune cells to enhance anti-tumor immunity, while lenvatinib inhibits multiple receptor tyrosine kinases to suppress tumor angiogenesis and growth.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Adjuvant tislelizumab plus lenvatinib TARGET	Adjuvant tislelizumab plus lenvatinib	Guangxi Medical University	phase 3	PD-1 inhibitor + multi-targeted tyrosine kinase inhibitor combination	PD-1 (tislelizumab); FGFR, VEGFR, RET, KIT (lenvatinib)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1 inhibitor + multi-targeted tyrosine kinase inhibitor combination class)

Guangxi Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Adjuvant tislelizumab plus lenvatinib — Competitive Intelligence Brief. https://druglandscape.com/ci/adjuvant-tislelizumab-plus-lenvatinib. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab